Nasopharyngeal Diseases  >>  cisplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

17 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT00565448 / 2007-001211-33: Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

Completed
2
75
Europe, RoW
docetaxel, Taxotere®, XRP6976, cisplatin, 5-fluorouracil, 5-FU
Sanofi
Nasopharyngeal Neoplasms, Carcinoma
03/09
01/12
ENCORE, NCT00700440: Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy

Completed
2
100
RoW
C225 (cetuximab), Erbitux
Sun Yat-sen University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sichuan Cancer Hospital and Research Institute, Fujian Cancer Hospital, Fudan University, Cancer Hospital of Guizhou Province, First Affiliated Hospital of Guangxi Medical University, Central South University
Nasopharyngeal Carcinoma
04/09
04/09
NCT00439426: A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.

Completed
2
25
RoW
Oxaliplatin, capecitabine [Xeloda]
Hoffmann-La Roche
Nasopharyngeal Cancer
09/09
09/09
NCT00436293: Taxotere + Cisplatin in Nasopharyngeal Carcinoma

Completed
2
61
RoW
Docetaxel, Cisplatin
Sanofi
Nasopharyngeal Neoplasms
03/10
03/10
NCT00895245: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Terminated
2
6
US
fosaprepitant dimeglumine, cisplatin, CACP, CDDP, CPDD, DDP, Neoplatin, palonosetron hydrochloride, Aloxi, RS 25259-197, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, Decaspray, DM, DXM, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy, 3-D conformal radiotherapy or IMRT
University of Washington, National Cancer Institute (NCI)
Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
09/10
02/11
NCT00603915: A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer

Completed
2
20
Canada
Gemcitabine, Carboplatin/Cisplatin, erlotinib
University Health Network, Toronto, Hoffmann-La Roche
Nasopharyngeal Cancer
12/10
04/11
NCT00697905: Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma

Completed
2
18
RoW
Gemcitabine, Carboplatin, Cisplatin, 5-fluorouracil (5-FU)
Ministry of Health, Malaysia
Nasopharyngeal Carcinoma
05/11
05/11
NCT00747799: Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
54
RoW
Sorafenib plus Cisplatin and 5-fluorouracil
Sun Yat-sen University
Nasopharyngeal Neoplasms
05/11
11/11
NCT00408694: Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Checkmark Data-HNC
Jan 2012 - Jan 2012: Data-HNC
Checkmark P2 data
Dec 2011 - Dec 2011: P2 data
Completed
2
46
US, Canada
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy
National Cancer Institute (NCI), Radiation Therapy Oncology Group
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7
12/11
12/11
NCT01682031: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

Terminated
2
18
US, RoW
selenomethionine, placebo, PLCB, cisplatin, CACP, CDDP, CPDD, DDP, radiation therapy, irradiation, radiotherapy, therapy, radiation, quality-of-life assessment, quality of life assessment
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Xerostomia
04/12
06/12
NCT00410826: Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Checkmark
Mar 2013 - Mar 2013: 
Completed
2
204
US
erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, cisplatin, CACP, CDDP, CPDD, DDP, 3-dimensional conformal radiation therapy, 3D-CRT, conformal radiation therapy, intensity-modulated radiation therapy, IMRT, quality-of-life assessment, quality of life assessment
University of Washington, National Cancer Institute (NCI)
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
05/12
 
NCT01596868: GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

Completed
2
60
RoW
gemcitabine and cisplatin, GP, docetaxel and cisplatin, TP
Air Force Military Medical University, China
Nasopharyngeal Squamous Cell Carcinoma, Toxicity Due to Radiotherapy
10/13
10/13
NCT01797900: The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Completed
2
130
RoW
Cisplatin, Paclitaxel, IMRT, intensity-modulated radiotherapy
Chinese Academy of Medical Sciences
Nasopharyngeal Neoplasms
09/14
09/14
NCT01616849: Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Completed
2
39
RoW
cisplatin and 5-Fu combined with nimotuzumab
Sun Yat-sen University, Fujian Cancer Hospital, First People's Hospital of Foshan, People's Hospital of Guangxi, Guangxi Medical University, Guangzhou Medical University, Hubei Cancer Hospital, Hunan Provincial Cancer Hospital, Hangzhou Cancer Hospital, Wuhan Union Hospital, China, Tongji Hospital, Jiangxi Provincial Cancer Hospital, Affiliated Cancer Hospital of Shantou University Medical College, Wuhan University, Zhejiang Cancer Hospital
Stage IV Nasopharyngeal Carcinoma
07/15
07/15
NCT01326559: Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)

Completed
2
33
RoW
Docetaxel, Cisplatin, 5-FU and Cetuximab
Hong Kong Nasopharyngeal Cancer Study Group Limited, The University of Hong Kong, Sanofi, Merck Sharp & Dohme LLC, Roche Pharma AG
Nasopharyngeal Carcinoma
12/16
03/17
NCT01534585: Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Completed
1/2
48
RoW
Icotinib, Conmana, intensity-modulated radiotherapy, IMRT, Paclitaxel and Cisplatin, Quality of life, QoL, Epidermal growth factor receptor status, EGFR
Taizhou Hospital
Nasopharyngeal Carcinoma
02/13
02/15
NCT02035527: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed
1/2
3
US
sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, cisplatin, CACP, CDDP, CPDD, DDP, docetaxel, RP 56976, Taxotere, TXT, Correlative Studies, laboratory biomarker analysis
Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
04/17
04/17

Download Options